CAR T-cell therapies have revolutionized the treatment of various B-cell malignancies [1–3].
Although allogeneic stem cell transplantation first demonstrated the power of adoptive T-cell …

The remarkable success of chimeric antigen receptor (CAR)-engineered T cells in pre-B cell
acute lymphoblastic leukemia (ALL) and B cell lymphoma led to the approval of anti-CD19 …

Introduction Chimeric antigen receptor (CAR)-modified T-cell therapy has revolutionized the
treatment of relapsed/refractory B-cell malignancies including acute lymphoblastic leukemia …

Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment
landscape for patients with relapsed or refractory B-cell lymphoid cancers. 1 With studies …

Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in
relapsed/refractory (r/r) B cell malignancies, including in pediatric patients with acute …

Allogeneic chimeric antigen receptor T (CAR T) cells can offer advantages over autologous
T cell therapies, including the availability of “fit” cells for production, and elimination of risks …

Chimeric antigen receptor-T (CAR-T) cell therapy has made remarkable strides in treating
hematological malignancies. However, the widespread adoption of CAR-T cell therapy is …

Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

Chimeric antigen receptor (CAR) T-cell therapy, belonging to adoptive immune cells
therapy, utilizes engineered immunoreceptors to enhance tumor-specific killing. By now new …

CD19-targeted chimeric antigen receptor (CAR)-T cell therapy has shown high potential for
treating B-cell hematological malignancies and has been approved by the US FDA …